Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 19/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2696996 | 0.93 | CMA1 (0.55) | CMA1POLB | |
| SCHEMBL2698950 | 0.86 | CMA1 (0.43) | CMA1 | |
| SCHEMBL2697923 | 0.85 | CMA1 (0.59) | CMA1 | |
| SCHEMBL2697919 | 0.85 | CMA1 (0.59) | CMA1 | |
| SCHEMBL2696231 | 0.84 | CMA1 (0.43) | CMA1POLB | |
| SCHEMBL2697474 | 0.84 | CMA1 (0.45) | CMA1POLB | |
| SCHEMBL2695228 | 0.83 | CMA1 (0.55) | CMA1 | |
| SCHEMBL2697494 | 0.83 | CMA1 (0.59) | CMA1 | |
| SCHEMBL2697487 | 0.83 | CMA1 (0.59) | CMA1 | |
| SCHEMBL2695469 | 0.83 | CMA1 (0.58) | CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501749-B2 | Azaquinazolinediones chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-2391624-B1 | AZAQUINAZOLINEDIONES USEFUL AS CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | CMA1, SERPINB1, CTSC | CMA1 1/4885POLB 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.